

Auditor's Report on Annual Financial Results of M/s Ishita Drugs & Industries Ltd pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Ishita Drugs & Industries Ltd

We have audited the statement of Annual financial results of M/s **Ishita Drugs & Industries Ltd** for the year ended 31st March, 2019, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These statement is the responsibility of the company's management and has been approved by the Board of Directors. This statement has been prepared on the basis of the annual financial statements. Our responsibility is to express an opinion on these financial results based on our audit of such annual financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the period from 01st April, 2018 to 31st March, 2019.

The financial results include the results for the Quarter ended March 31, 2019, being the balancing figure between audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year, which were subject to limited review by us.

Date: 29/05/2019
Place: Ahmedabad

For and on behalf of
JAYMIN SHAH & ASSOCIATES
Chartered Accountants
Mayank Sancheti
Mayank Sancheti
M No 170863 Partner
UDIN 19170863AAAABD7628

ISHITA DRUGS AND INDUSTRIES LIMITED
CIN: L24231GJ1992PLC017054
Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170
Website: www.ishitadrugs.com
Contact: +91 7226995613

Audited Financial Results for the Quarter and Year Ended March 31, 2019

Amount in Lacs except Per Share data

Particulars	3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months Ended in the previous Year	Year to date figures for current year ended	Year to date figures for current year ended
	Audited	Un-audited	Audited	Audited	Audited
	31-Mar-19	31-Dec-18	31-Mar-18	31-Mar-19	31-Mar-18
1 INCOME					
Revenue from Operations	295.39	232.44	239.81	908.72	689.98
Other Income	12.23	0.48	5.81	16.34	11.93
Total Income	307.62	232.924	245.62	925.05	701.91
2 EXPENSES					
(a) Cost of Material Consumed	215.36	154.10	191.54	620.62	476.74
(b) Purchase of Stock-In-Trade	6.36	0.00	(3.70)	6.36	9.23
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	7.28	5.01	(1.15)	13.16	(12.71)
(d) Employee Benefit Expense	28.35	24.82	20.06	95.55	79.99
(e) Finance Cost	3.85	0.64	8.95	6.06	11.26
(f) Depreciation, Depletion and Amortisation Expense	3.62	4.66	3.11	15.59	13.61
(g) Other Expense	28.26	32.75	14.35	121.43	91.47
Total Other Expenses	28.259	32.751	14.35	121.43	91.469
Total Expenses	293.08	221.99	233.16	878.77	669.589
3 Total Profit before Exceptional Items and Tax	14.54	10.94	12.46	46.29	32.321
4 Exceptional Items	0	0	0.00	0.00	0
5 Total Profit before Tax	14.54	10.94	12.46	46.29	32.321
6 Tax Expense					
Current Tax	3.55	3.36	4.21	11.50	8.00
Deferred Tax	(0.37)	0.00	(0.46)	(0.37)	(0.46)
Total Tax Expenses	3.18	3.36	3.75	11.13	7.541
10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement		0.00	0.00	0.00	0
11 Net Profit Loss for the period from continuing operations	11.36	7.58	8.71	35.16	24.78

Jyoti Agrawal



12	Profit / (Loss) from discontinued operations before tax	0.00	0.00	0.00	0.00	0
13	Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00	0
14	Net Profit / (Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0
15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method					
		0.00	0.00	0.00	0.00	0
16	Total Profit / (Loss) for the period	11.36	7.58	8.71	35.16	24.78
17	Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00	0
18	Total Comprehensive Income for the Period	11.36	7.58	8.71	35.16	24.78
19	Total profit or loss attributable to					
	Profit or loss, attributable to owners of parents	0	0	0.00	0.00	0
	Total Profit or loss, attributable to non-controlling interests	0	0	0.00	0.00	0
20	Total comprehensive income for the period attributable to					
	Comprehensive Income for the period attributable to the owners of parents		0	0.00	0.00	0
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests		0	0	0	0
21	Details of Equity Share Capital					
	Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03	299.03
	Face Value of Equity Share Capital	10	10	10	10	10
22	Details of Debt Securities					
	Paid-Up Debt Capital	0	0	0	0	0
	Face Value of Debt Securities	0	0	0	0	0
23	Reserves Excluding Revaluation Reserves	0	0	0	0	0
24	Debenture Redemption Reserve	0	0	0	0	0
25	Earnings Per Share					
(i)	Earnings Per Share for continuing operations					
	Basic Earnings / (Loss) per share from continuing operations	0.38	0.26	0.29	1.18	0.83
	Diluted Earnings / (Loss) per share from continuing operations	0.38	0.26	0.29	1.18	0.83
(ii)	Earnings Per Share for discontinued operations					
	Basic Earnings / (Loss) per share from discontinued operations	0	0	0	0	0
	Diluted Earnings / (Loss) per share from discontinued operations	0	0	0	0	0
(iii)	Earnings per Equity Share					
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.38	0.26	0.29	1.18	0.83
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.38	0.26	0.29	1.18	0.83
26	Debt Equity Ratio	0	0		0	0
27	Debt Service Coverage Ratio	0	0		0	0
28	Interest Service Coverage Ratio	0	0		0	0

As per approval



NOTES

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on May 29,2019
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter and year ended 31st March, 2019 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, **ISHITA DRUGS AND INDUSTRIES LIMITED**



Jagdish Agrawal

JAGDISH AGRAWAL

MANAGING DIRECTOR

DIN: 01031687

Place	Ahmedabad		
Date	29-May-19		

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

Statement of Assets and Liabilities

Amount in ₹

Particulars	Year Ended	Previous Year Ended	
	12 Months Ended	12 Months Ended	
	Audited	Audited	
	31-Mar-19	31-Mar-18	
ASSETS			
1	Non-current assets		
	Property, plant and equipment	12998979	11879886
	Capital work-in-progress		
	Investment property		
	Goodwill		
	Other intangible assets		
	Intangible assets under development		
	Biological assets other than bearer plants		
	Investments accounted for using equity method		
	Non-current financial assets	12998979	11879886
	Non-current investments	1592254	1592254
	Trade receivables, non-current		
	Loans, non-current		
	Other non-current financial assets	506200	498200
	Total Non-current financial assets	2098454	2090454
	Deferred tax assets (net)		
	Other non-current assets		
	Total Non-current Assets	15097433	13970340
2	Current assets		
	Inventories	7387752	7200886
	Current financial assets		
	Current investments	38787641	29936585
	Trade receivables, current	11610912	8215528
	Cash and cash equivalents	239078	251974
	Bank balance other than cash and cash equivalents	10064472	6500088
	Loans, current	26337	736491
	Other current financial assets	168263	5377578
	Total current financial assets	60896703	51018244
	Current tax assets (net)		
	Other current assets		
	Total Current Assets	0	0
3	Non-current assets classified as held for sale		
4	Regulatory deferral account debit balances and related deferred tax Assets		
	TOTAL ASSETS	83381888	72189470

Dephin Agrawal



EQUITIES AND LIABILITIES			
1	Equity		
	Equity attributable to owners of Parent		
	Equity share capital	29903000	29903000
	Other equity	34336519	30720893
	Total Equity attributable to owners of Parent	64239519	60623893
	Non controlling interest		
	Total Equity	64239519	60623893
2	Liabilities		
	Non-current liabilities		
	Non-current financial liabilities		
	Borrowing, non-current	1224637	849413
	Trade payables, non-current		
	Other non-current financial liabilities		
	Total Non-current financial liabilities	1224637	849413
	Provisions, non-current		
	Deferred tax liabilities (net)	556394	593317
	Deferred government grants, Non-current Other non-current liabilities		
	Total Non-current liabilities	556394	593317
	Current liabilities		
	Current financial liabilities		
	Borrowing, current	821829	417537
	Trade payables, current	13785833	5616188
	Other current financial liabilities		
	Total current financial liabilities	14607662	6033725
	Other current liabilities	1039076	2932592
	Provisions, current	1714600	1156530
	Current tax liabilities (Net)		
	Deferred government grants, Current		
	Total current liabilities	2753676	4089122
3	Liabilities directly associated with assets in disposal group classified as held for sale		
4	Regulatory deferral account credit balances and related deferred tax liability		
	Total Liabilities	0	0
	Total Equity and Liabilities	83381888	72189470

For, ISHITA DRUGS AND INDUSTRIES LIMITED



Jagdish Agrawal

JAGDISH AGRAWAL

MANAGING DIRECTOR

Place Ahmedabad

Date 29-May-19

DIN: 01031687



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Phone : +91 7226995613/14/15 | +91 79 2646 8353, 4002 3839 | Fax : +91 79 26404961

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : ishitadrugs@gmail.com | ishitadrugs@vsnl.net | URL : www.ishitadrugs.com

Date: 29th May, 2019

To
The Company Section
The Bombay Stock Exchange
Phiroze Jijibhoy Towers
Dalal Street, Bombay-400 001

Security Code: 524400

Dear Sir,

Sub: Declaration regarding unmodified Audit report in respect of standalone financial statement for the year 2018-19 under SEBI (LODR) Regulations, 2015

We hereby declare that we are hereby submitting the Audit Report in respect of standalone financial statement for the financial year 2018-19 along with financial results on 29th May, 2019. Pursuant to the requirement under 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015 we hereby declare that the auditors have expressed an unmodified opinion in their audit reports on standalone financial statement of the Company for the financial year 2018-19.

Thanking You.

For Ishita Drugs and Industries Limited

Authorized Signatory



"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359